Monday, May 21, 2018
 
 
Company News: Page (1) of 1 - 01/09/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
AerNos Announces Wearable Air Pollution Monitor at CES 2018
 
(January 09, 2018)
AerNos Announces Wearable Air Pollution Monitor at CES 2018

In a press conference at CES 2018, AerNos, an innovator in nano gas sensors, unveiled a game-changing wearable device for air pollution detection and research. Called AerBand Research, the wearable or clip-able device will revolutionize how scientific studies track and study human exposure to harmful air pollutants. AerBand Research will be shipping to customers in the first half of 2018 and available to consumers in 2019.

By monitoring the personal surrounding air of research participants 24/7, AerBand will be a powerful new tool for dramatically expanding scientists' understanding of the effects of air pollution on human health and for reducing exposure and improving health.

“AerBand Research is a breakthrough that will lead to better answers to the most urgent questions I'm hearing from parents everyday – what pollutants are we exposed too, what matters and how do we avoid them," said Christopher Gavigan, Honest Company Co-Founder and AerNos Advisor. “Air pollution monitoring today does not tell me what I'm breathing right here, right now. It significantly limits health research and our ability to take action. AerBand is about to change that."



AerBand Research is designed to be worn or attached via clip for always-on air pollution monitoring. AerNos' nano gas sensor technology enables simultaneous detection of multiple indoor and outdoor airborne toxins to ppb levels. AerBand pairs with an end user App for tracking real-time pollution levels, historical information and for accessing recommended actions. Organizations access data via the AerBand Data Cloud API – including detailed air pollution readings, geolocation and usage information.

“With the introduction of AerBand, our vision to introduce a wearable product that can significantly change health and wellness in such a profound way is taking shape," said Sundip R. Doshi, Founder and CEO of AerNos. “We are excited to utilize AerCNT, our breakthrough in nanotechnology to bring gas sensing applications to the market."

Air pollution is a significant contributor to illness, disease and death around the world, with health effects that include birth defects, asthma and other lung diseases, heart disease, cancer, ADHD and other diseases. The Lancet Commission on Pollution and Health recently reported that pollution is the largest cause of premature death, 16% of all premature deaths worldwide, and air pollution is the biggest contributor.

As a part of its vision of a trillion nano gas sensor network, in addition to announcing AerBand Research, AerNos announced IoT nano gas sensors for integration into Smart City and Smart Home products.

About AerNos at CES 2018
AerNos will be at Booth #42367, located at Tech West, Sands Expo, Level 2. Visit our CES 2018 listing and watch the AerNos Video.

About AerNos
AerNos, Inc. develops application-specific nano gas sensors based on its breakthrough and proprietary AerCNT Technology to detect harmful gases in the environment. AerNos nano gas sensors are designed to be easily integrated into consumer and commercial product lines such as standalone monitoring devices, non-stationary devices (drones, industrial robots, construction equipment, etc.), modes of transportation, wearables, smartphones, and the IoT. For more information, please visit http://www.AerNos.com. You may also contact us at media(at)AerNos(dot)com.

Read the full story at http://www.prweb.com/releases/2018/01/prweb15063453.htm.


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   CEN - Consumer Electronics Net ,   CEN - Phones ,   VideoBasedTutorials ,   HTN - Health Technology Net
Related Newsletter: CEN - Gadgets Newsletter ,   Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
  • Regenerative Medicine Market Analysis Study Found Huge Boom By Rising Prevalence Of Chronic Diseases And Genetic Disorders Till 2025: Grand View Research,Inc.
  • Global Molecular Diagnostics Markets, 2016-2024 - Focus on Infectious Disease Testing, Blood Screening, Cancer Screening & Other Applications
  • Global Sleep Apnea Diagnostic and Therapeutic Devices Strategic Business Report 2018
  • Global Sleep Apnea Diagnostic and Therapeutic Devices: 2016/18-2024 Strategic Business Analysis & Forecast Report - mHealth-Enabled Sleep Tracking Devices Gain Ground

    Cancer
  • Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.
  • Altogen Labs xenograft services for drug development studies of anti-cancer therapeutics
  • HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage
  • Dr. Haydee Gonzalez Hidalgo joins The Oncology Institute of Hope and Innovation
  • eClinical Solutions Market Size Is Projected To Reach $13 Billion By 2024
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines